苯扎贝特对高脂蛋白血症患者血清脂蛋白浓度的剂量反应研究。

Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia.

作者信息

Olsson A G, Lang P D

出版信息

Atherosclerosis. 1978 Dec;31(4):421-8. doi: 10.1016/0021-9150(78)90137-5.

Abstract

The effect of bezafibrate in the dosages 450, 900 and 1350 mg daily on serum lipoprotein concentrations were studied in 20 subjects with primary hyperlipoproteinaemia (16 of type IV, 2 of type II B, 1 of type III). Except for LDL cholesterol maximum effects were obtained with 450 mg daily. Total serum cholesterol and triglycerides (TG) fell significantly. Mean very low density lipoprotein (VLDL) TG fell by 54%. The maximum effect on low density lipoprotein was obtained with 900 mg daily. The effect was highly dependent on initial concentrations, decreases being observed above 4 mmoles/l and increases below that concentration. High density lipoprotein cholesterol increased by 31% (P less than 0.01) independently of the VLDL decrease. Three subjects suffered gastrointestinal side-effects on 1350 mg daily. Only benign reversible changes were noted on non-lipid measurements. Bezafibrate is a well-tolerated drug with a good VLDL TG lowering effect. It is particularly effective in increasing HDL cholesterol concentrations.

摘要

对20例原发性高脂蛋白血症患者（IV型16例、II B型2例、III型1例）研究了每日剂量450、900和1350毫克的苯扎贝特对血清脂蛋白浓度的影响。除低密度脂蛋白胆固醇外，每日450毫克可产生最大效应。血清总胆固醇和甘油三酯（TG）显著下降。平均极低密度脂蛋白（VLDL）TG下降了54%。每日900毫克对低密度脂蛋白产生最大效应。该效应高度依赖于初始浓度，在4毫摩尔/升以上观察到下降，在该浓度以下观察到上升。高密度脂蛋白胆固醇增加了31%（P<0.01），与VLDL下降无关。3例患者每日服用1350毫克出现胃肠道副作用。在非脂质测量中仅发现良性可逆变化。苯扎贝特是一种耐受性良好的药物，具有良好的降低VLDL TG的作用。它在增加高密度脂蛋白胆固醇浓度方面特别有效。